tiprankstipranks
AnaptysBio (ANAB)
NASDAQ:ANAB
US Market
ANAB
AnaptysBio
RESEARCH TOOLSreports
Want to see ANAB full AI Analyst Report?

AnaptysBio (ANAB) Stock Forecast & Price Target

686 Followers
See the Price Targets and Ratings of:

ANAB Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
AnaptysBio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ANAB Stock 12 Month Forecast

Average Price Target

$80.50
▲(19.24% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for AnaptysBio in the last 3 months. The average price target is $80.50 with a high forecast of $140.00 and a low forecast of $50.00. The average price target represents a 19.24% change from the last price of $67.51.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","141":"$141","44.25":"$44.3","76.5":"$76.5","108.75":"$108.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$80.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,44.25,76.5,108.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.67,62.15692307692308,68.64384615384616,75.13076923076923,81.61769230769231,88.10461538461539,94.59153846153846,101.07846153846154,107.56538461538462,114.05230769230769,120.53923076923077,127.02615384615385,133.51307692307694,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.67,57.58,59.49,61.4,63.31,65.22,67.13,69.04,70.95,72.86,74.77,76.68,78.59,{"y":80.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.67,55.23384615384616,54.79769230769231,54.361538461538466,53.925384615384615,53.48923076923077,53.05307692307692,52.61692307692308,52.18076923076923,51.744615384615386,51.308461538461536,50.87230769230769,50.43615384615384,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.571,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.097,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.457,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.551,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.31,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.383,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.535,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.315,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.688,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.601,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.814,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.76,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.67,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$140.00Average Price Target$80.50Lowest Price Target$50.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on ANAB
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), GeoVax Labs (NASDAQ: GOVX) and Vir Biotechnology (NASDAQ: VIR)
J.P. Morgan Analyst forecast on ANAB
Anupam Rama
J.P. Morgan
J.P. Morgan
$69→$70
Buy
3.69%
Upside
Reiterated
05/22/26
J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)
Piper Sandler Analyst forecast on ANAB
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$93
Buy
37.76%
Upside
Reiterated
05/13/26
Analysts Are Bullish on These Healthcare Stocks: AnaptysBio (ANAB), Legend Biotech (LEGN)
Barclays Analyst forecast on ANAB
Etzer Darout
Barclays
Barclays
$63→$75
Buy
11.09%
Upside
Assigned
05/13/26
Barclays Remains a Buy on AnaptysBio (ANAB)
TD Cowen Analyst forecast on ANAB
Joseph Thome
TD Cowen
TD Cowen
$65.58→$75
Buy
11.09%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), ProQR (NASDAQ: PRQR) and OptimizeRx (NASDAQ: OPRX)
UBS Analyst forecast on ANAB
Michael Yee
UBS
UBS
$60→$76
Buy
12.58%
Upside
Reiterated
05/13/26
AnaptysBio price target raised to $76 from $60 at UBSAnaptysBio price target raised to $76 from $60 at UBS
Wedbush Analyst forecast on ANAB
David Nierengarten
Wedbush
Wedbush
$60→$75
Buy
11.09%
Upside
Reiterated
03/31/26
Wedbush Remains a Buy on AnaptysBio (ANAB)
H.C. Wainwright Analyst forecast on ANAB
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$55→$66
Buy
-2.24%
Downside
Reiterated
03/30/26
AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
Truist Financial Analyst forecast on ANAB
Joon Lee
Truist Financial
Truist Financial
$36→$50
Hold
-25.94%
Downside
Reiterated
03/09/26
Truist Financial Keeps Their Hold Rating on AnaptysBio (ANAB)
Stifel Nicolaus Analyst forecast on ANAB
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$56→$85
Buy
25.91%
Upside
Reiterated
03/05/26
Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS)
Guggenheim Analyst forecast on ANAB
Yatin Suneja
Guggenheim
Guggenheim
$140
Buy
107.38%
Upside
Reiterated
03/04/26
Guggenheim Reaffirms Their Buy Rating on AnaptysBio (ANAB)
Wells Fargo Analyst forecast on ANAB
Derek Archila
Wells Fargo
Wells Fargo
$81
Buy
19.98%
Upside
Reiterated
12/16/25
AnaptysBio (ANAB) Receives a Buy from Wells Fargo
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on ANAB
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), GeoVax Labs (NASDAQ: GOVX) and Vir Biotechnology (NASDAQ: VIR)
J.P. Morgan Analyst forecast on ANAB
Anupam Rama
J.P. Morgan
J.P. Morgan
$69→$70
Buy
3.69%
Upside
Reiterated
05/22/26
J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)
Piper Sandler Analyst forecast on ANAB
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$93
Buy
37.76%
Upside
Reiterated
05/13/26
Analysts Are Bullish on These Healthcare Stocks: AnaptysBio (ANAB), Legend Biotech (LEGN)
Barclays Analyst forecast on ANAB
Etzer Darout
Barclays
Barclays
$63→$75
Buy
11.09%
Upside
Assigned
05/13/26
Barclays Remains a Buy on AnaptysBio (ANAB)
TD Cowen Analyst forecast on ANAB
Joseph Thome
TD Cowen
TD Cowen
$65.58→$75
Buy
11.09%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), ProQR (NASDAQ: PRQR) and OptimizeRx (NASDAQ: OPRX)
UBS Analyst forecast on ANAB
Michael Yee
UBS
UBS
$60→$76
Buy
12.58%
Upside
Reiterated
05/13/26
AnaptysBio price target raised to $76 from $60 at UBSAnaptysBio price target raised to $76 from $60 at UBS
Wedbush Analyst forecast on ANAB
David Nierengarten
Wedbush
Wedbush
$60→$75
Buy
11.09%
Upside
Reiterated
03/31/26
Wedbush Remains a Buy on AnaptysBio (ANAB)
H.C. Wainwright Analyst forecast on ANAB
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$55→$66
Buy
-2.24%
Downside
Reiterated
03/30/26
AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
Truist Financial Analyst forecast on ANAB
Joon Lee
Truist Financial
Truist Financial
$36→$50
Hold
-25.94%
Downside
Reiterated
03/09/26
Truist Financial Keeps Their Hold Rating on AnaptysBio (ANAB)
Stifel Nicolaus Analyst forecast on ANAB
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$56→$85
Buy
25.91%
Upside
Reiterated
03/05/26
Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS)
Guggenheim Analyst forecast on ANAB
Yatin Suneja
Guggenheim
Guggenheim
$140
Buy
107.38%
Upside
Reiterated
03/04/26
Guggenheim Reaffirms Their Buy Rating on AnaptysBio (ANAB)
Wells Fargo Analyst forecast on ANAB
Derek Archila
Wells Fargo
Wells Fargo
$81
Buy
19.98%
Upside
Reiterated
12/16/25
AnaptysBio (ANAB) Receives a Buy from Wells Fargo
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AnaptysBio

3 Months
Joseph ThomeTD Cowen
Success Rate
13/19 ratings generated profit
68%
Average Return
+17.94%
Copying Joseph Thome's trades and holding each position for 3 Months would result in 68.42% of your transactions generating a profit, with an average return of +17.94% per trade.
1 Year
Alex Thompson CFAStifel Nicolaus
Success Rate
9/11 ratings generated profit
82%
Average Return
+124.19%
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +124.19% per trade.
2 Years
Derek ArchilaWells Fargo
Success Rate
13/13 ratings generated profit
100%
Average Return
+261.51%
Copying Derek Archila's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +261.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ANAB Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
5
5
3
2
0
Buy
3
9
14
22
13
Hold
0
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
15
18
25
13
In the current month, ANAB has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ANAB average Analyst price target in the past 3 months is 80.50.
Each month's total comprises the sum of three months' worth of ratings.

ANAB Financial Forecast

ANAB Earnings Forecast

Next quarter’s earnings estimate for ANAB is -$0.27 with a range of -$0.89 to $0.34. The previous quarter’s EPS was -$1.84. ANAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ANAB has Performed in-line its overall industry.
Next quarter’s earnings estimate for ANAB is -$0.27 with a range of -$0.89 to $0.34. The previous quarter’s EPS was -$1.84. ANAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ANAB has Performed in-line its overall industry.

ANAB Sales Forecast

Next quarter’s sales forecast for ANAB is $23.98M with a range of $0.00 to $37.00M. The previous quarter’s sales results were $25.56M. ANAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ANAB has Performed in-line its overall industry.
Next quarter’s sales forecast for ANAB is $23.98M with a range of $0.00 to $37.00M. The previous quarter’s sales results were $25.56M. ANAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ANAB has Performed in-line its overall industry.

ANAB Stock Forecast FAQ

What is ANAB’s average 12-month price target, according to analysts?
Based on analyst ratings, AnaptysBio’s 12-month average price target is 80.50.
    What is ANAB’s upside potential, based on the analysts’ average price target?
    AnaptysBio has 19.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ANAB a Buy, Sell or Hold?
          AnaptysBio has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is AnaptysBio’s price target?
            The average price target for AnaptysBio is 80.50. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $140.00 ,the lowest forecast is $50.00. The average price target represents 19.24% Increase from the current price of $67.51.
              What do analysts say about AnaptysBio?
              AnaptysBio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of ANAB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.